Asia Pacific Doxorubicin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Drug Formulation (Lyophilized Powder and Doxorubicin Injection), Application (Breast Cancer, Kidney Cancer, Liver Cancer, Sarcoma, Ovarian Cancer, Lung Cancer, Leukemia, Multiple Myeloma, and Others), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
The APAC doxorubicin market is expected to grow from US$ 257.33 million in 2022 to US$ 386.82 million by 2028; it is estimated to grow at a CAGR of 7.0% from 2022 to 2028.
Cancer treatment has yielded better results, but access to medicines has become a problem across the region, especially in low- and middle-income countries. However, replacing it with a generic drug can save significantly. The doxorubicin market is characterized by the presence of large and small companies. Players are taking up product launches, regional expansions, and technological advancements to increase their market share. Continuous innovations and technological advancements result in safer and more effective doxorubicin drugs, increasing acceptance among patients and medical societies. Several developments have taken place in the recent years. For instance, in September 2020, Zydus Cadila received final approval for the commercialization of its generic doxorubicin hydrochloride liposome injection. Further, in September 2018, Hikma Pharmaceuticals PLC launched Adriamycin (DOXOrubicin HCl) for injection as a part of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node association following resection of primary breast cancer. Thus, approval of generic substitution for frequently used chemotherapy drugs, such as doxorubicin, in treating common cancers has a vast potential to increase significant cost savings and rising access to cancer treatments in several countries across the region.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC doxorubicin market. The APAC doxorubicin market is expected to grow at a good CAGR during the forecast period.
APAC Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
Get more information on this report :
APAC Doxorubicin Market Segmentation
The APAC doxorubicin market is segmented based on drug formulation, application, distribution channel, and country. Based on drug formulation, the APAC doxorubicin market is bifurcated into lyophilized powder and doxorubicin injection. The lyophilized powder segment dominated the market in 2022. Based on application, the APAC doxorubicin market is segmented into breast cancer, kidney cancer, liver cancer, sarcoma, ovarian cancer, lung cancer, leukemia, multiple myeloma, and others. The breast cancer segment dominated the market in 2022. Based on distribution channel, the APAC doxorubicin market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2022. Based on country, the APAC doxorubicin market has been categorized into China, India, Japan, South Korea, Australia, and Rest of APAC. Our regional analysis states that China dominated the market in 2022.
Accord Healthcare; Baxter International Inc.; Cipla Inc.; Dr. Reddy's Laboratories; Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.); Meiji Holdings Co., Ltd.; Novartis AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd; and Zydus Cadila are among the leading companies in the APAC doxorubicin market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Doxorubicin Market – By Drug Formulation
1.3.2 APAC Doxorubicin Market – By Application
1.3.3 APAC Doxorubicin Market – By Distribution Channel
1.3.4 APAC Doxorubicin Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Doxorubicin Market – Market Landscape
4.1 Overview
4.2 APAC PEST Analysis
4.3 Expert Opinion
5. APAC Doxorubicin Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cancer
5.1.2 Increasing Preference for Chemotherapy
5.2 Market Restraints
5.2.1 Potential Side-effects Associated with Doxorubicin
5.3 Market Opportunities
5.3.1 Increasing Government Funding, Guidance, and Technical Assistance for Cancer Prevention
5.4 Future Trends
5.4.1 Increasing Approval of Generic Products
5.5 Impact Analysis
6. Doxorubicin Market– APAC Analysis
6.1 APAC Doxorubicin Market Revenue Forecast and Analysis
7. APAC Doxorubicin Market Analysis – By Drug Formulation
7.1 Overview
7.2 APAC Doxorubicin Market Share, By Drug Formulation 2022 & 2028 (%)
7.3 Lyophilized Powder
7.3.1 Overview
7.3.2 Lyophilized Powder: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
7.4 Doxorubicin Injection
7.4.1 Overview
7.4.2 Doxorubicin Injection: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8. APAC Doxorubicin Market Analysis – By Application
8.1 Overview
8.2 APAC Doxorubicin Market Share, By Application 2022 & 2028 (%)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.4 Kidney Cancer
8.4.1 Overview
8.4.2 Kidney Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.5 Liver Cancer
8.5.1 Overview
8.5.2 Liver Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.6 Sarcoma
8.6.1 Overview
8.6.2 Sarcoma: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.7 Ovarian Cancer
8.7.1 Overview
8.7.2 Ovarian Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.8 Lung Cancer
8.8.1 Overview
8.8.2 Lung Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.9 Leukemia
8.9.1 Overview
8.9.2 Leukemia: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.10 Multiple Myeloma
8.10.1 Overview
8.10.2 Multiple Myeloma: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.11 Others
8.11.1 Overview
8.11.2 Others: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
9. APAC Doxorubicin Market Analysis – By Disribution Channel
9.1 Overview
9.2 APAC Doxorubicin Market Share, By Disribution Channel 2022 & 2028 (%)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
9.5 Online Pharmacy
9.5.1 Overview
9.5.2 Online Pharmacy: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
10. APAC Doxorubicin Market Analysis – By Country
10.1 Overview
10.1.1 APAC: Doxorubicin Market, by Country, 2022 & 2028 (%)
10.1.1.1 China: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.1 China: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.2 China: Doxorubicin Market, By Drug Formulation, 2019–2028 (US$ Million)
10.1.1.1.3 China: Doxorubicin Market, by Application, 2019–2028 (US$ Million)
10.1.1.1.4 China: Doxorubicin Market, By Distribution Channel, 2019–2028 (US$ Million)
10.1.1.2 Japan: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.1 Japan: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.2 Japan: Doxorubicin Market, By Drug Formulation, 2019–2028 (US$ Million)
10.1.1.2.3 Japan: Doxorubicin Market, By Application, 2019–2028 (US$ Million)
10.1.1.2.4 Japan: Doxorubicin Market, By Distribution Channel, 2019–2028 (US$ Million)
10.1.1.3 India: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.1 India: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.2 India: Doxorubicin Market, By Drug Formulation, 2019–2028 (US$ Million)
10.1.1.3.3 India: Doxorubicin Market, By Application, 2019–2028 (US$ Million)
10.1.1.3.4 India: Doxorubicin Market, By Distribution Channel, 2019–2028 (US$ Million)
10.1.1.4 South Korea: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.1 South Korea: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.2 South Korea: Doxorubicin Market, By Drug Formulation, 2019–2028 (US$ Million)
10.1.1.4.3 South Korea: Doxorubicin Market, By Application, 2019–2028 (US$ Million)
10.1.1.4.4 South Korea: Doxorubicin Market, By Distribution Channel, 2019–2028 (US$ Million)
10.1.1.5 Australia: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.1 Australia: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.2 Australia: Doxorubicin Market, By Drug Formulation, 2019–2028 (US$ Million)
10.1.1.5.3 Australia: Doxorubicin Market, By Application, 20192028 (US$ Million)
10.1.1.5.4 Australia: Doxorubicin Market, By Distribution Channel, 2019–2028 (US$ Million)
10.1.1.6 Rest of APAC: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.1 Rest of APAC: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.2 Rest of APAC: Doxorubicin Market, By Drug Formulation, 2019–2028 (US$ Million)
10.1.1.6.3 Rest of APAC: Doxorubicin Market, By Application, 2019–2028 (US$ Million)
10.1.1.6.4 Rest of APAC: Doxorubicin Market, By Distribution Channel, 2019–2028 (US$ Million)
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Accord Healthcare
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Cipla Inc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Dr. Reddy's Laboratories
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Meiji Holdings Co., Ltd.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.)
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Novartis AG
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Pfizer Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Sun Pharmaceutical Industries Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Baxter International Inc.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Zydus Cadila
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. APAC Doxorubicin Market, Revenue and Forecast, 2019–2028 (US$ Mn)
Table 2. Incidence, Mortality, and Prevalence, by Cancer Site (2020)
Table 3. China: Doxorubicin Market, By Drug Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 4. China: Doxorubicin Market, by Application – Revenue and forecast to 2028 (US$ Million)
Table 5. China: Doxorubicin Market, By Distribution Channel– Revenue and Forecast to 2028 (US$ Million)
Table 6. Japan: Doxorubicin Market, By Drug Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 7. Japan: Doxorubicin Market, By Application – Revenue and Forecast to 2028 (US$ Million)
Table 8. Japan: Doxorubicin Market, By Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 9. Incidence, Mortality, and Prevalence by Cancer Site (2020)
Table 10. India: Doxorubicin Market, By Drug Formulation– Revenue and Forecast to 2028 (US$ Million)
Table 11. India: Doxorubicin Market, By Application – Revenue and Forecast to 2028 (US$ Million)
Table 12. India: Doxorubicin Market, By Distribution Channel– Revenue and Forecast to 2028 (US$ Million)
Table 13. South Korea: Doxorubicin Market, By Drug Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 14. South Korea: Doxorubicin Market, By Application – Revenue and Forecast to 2028 (US$ Million)
Table 15. South Korea: Doxorubicin Market, By Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 16. Australia: Doxorubicin Market, By Drug Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 17. Australia: Doxorubicin Market, By Application – Revenue and Forecast to 2028 (US$ Million)
Table 18. Australia: Doxorubicin Market, By Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 19. Rest of APAC: Doxorubicin Market, By Drug Formulation – Revenue and Forecast to 2028 (US$ Million)
Table 20. Rest of APAC: Doxorubicin Market, By Application – Revenue and Forecast to 2028 (US$ Million)
Table 21. Rest of APAC: Doxorubicin Market, By Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 22. Organic Developments Done By Companies
Table 23. Inorganic Developments Done by Companies
Table 24. Glossary of Terms
LIST OF FIGURES
Figure 1. APAC Doxorubicin Market Segmentation
Figure 2. APAC Doxorubicin Market Segmentation, By Country
Figure 3. APAC Doxorubicin Market Overview
Figure 4. APAC Doxorubicin Market, By Drug Formulation
Figure 5. APAC Doxorubicin Market, By Country
Figure 6. APAC: PEST Analysis
Figure 7. APAC Doxorubicin Market Impact Analysis Of Driver And Restraints
Figure 8. APAC Doxorubicin Market– Revenue Forecast and Analysis
Figure 9. APAC Doxorubicin Devices Market Share, By Drug Formulation 2022 & 2028 (%)
Figure 10. APAC Lyophilized Powder: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 11. APAC Doxorubicin Injection: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 12. APAC Doxorubicin Devices Market Share, By Application 2022 & 2028 (%)
Figure 13. APAC Breast Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 14. APAC Kidney Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 15. APAC Liver Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 16. APAC Sarcoma: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 17. APAC Ovarian Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 18. APAC Lung Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 19. APAC Leukemia: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 20. APAC Multiple Myeloma: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 21. APAC Others: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 22. APAC Doxorubicin Devices Market Share, By Disribution Channel 2022 & 2028 (%)
Figure 23. APAC Hospital Pharmacy: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 24. APAC Retail Pharmacy: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 25. APAC Online Pharmacy: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
Figure 26. APAC Doxorubicin Market, by Key Country – Revenue (2022) (US$ Million)
Figure 27. APAC: Doxorubicin Market, by Country, 2022 & 2028 (%)
Figure 28. China: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Japan: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. India: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. South Korea: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Australia: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Rest of APAC: Doxorubicin Market – Revenue and Forecast to 2028 (US$ Million)
- Accord Healthcare
- Baxter International Inc.
- Cipla Inc.
- Dr. Reddy's Laboratories
- Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.)
- Meiji Holdings Co., Ltd.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Zydus Cadila
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC doxorubicin market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the APAC doxorubicin market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the doxorubicin market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution